Erik Thomas Bodor

US Patent:

20040029911, Feb 12, 2004

Filed:

Aug 6, 2002

Appl. No.:

10/213428

Inventors:

Harold Kohn - Chapel Hill NC, US
T. Harden - Carrboro NC, US
Myoung Kim - Chapel Hill NC, US
Erik Bodor - Durham NC, US

International Classification:

C07D453/02

US Classification:

514/305000, 546/133000

Abstract:

The present invention discloses novel cholinergic receptor ligands. The present invention also relates to the synthesis of substituted derivatives of aza-bridged bicyclic amines for use as muscarinic receptor ligands as well as methods of regulating function of certain cholinergic receptors, and hence acting as antagonists, agonists and partial agonists at certain specific cholinergic receptor subtypes. The present invention also relates to methods for treating disorders associated with cholinergic receptors.

US Patent:

20050137225, Jun 23, 2005

Filed:

Feb 14, 2005

Appl. No.:

11/057748

Inventors:

Harold Kohn - Chapel Hill NC, US
T. Harden - Carrboro NC, US
Myoung Kim - Chapel Hill NC, US
Erik Bodor - Durham NC, US

International Classification:

C07D451/02
A61K031/46

US Classification:

514304000, 546125000, 546124000

Abstract:

The present invention discloses novel cholinergic receptor ligands. The present invention also relates to the synthesis of substituted derivatives of aza-bridged bicyclic amines for use as muscarinic receptor ligands as well as methods of regulating function of certain cholinergic receptors, and hence acting as antagonists, agonists and partial agonists at certain specific cholinergic receptor subtypes. The present invention also relates to methods for treating disorders associated with cholinergic receptors.

US Patent:

20220339103, Oct 27, 2022

Filed:

Apr 19, 2022

Appl. No.:

17/724474

Inventors:

- Miami FL, US
Erik T BODOR - Miami FL, US

International Classification:

A61K 9/14
A61K 45/06
A61P 11/06
A61K 9/00
A61K 31/573
A61K 31/58

Abstract:

Provided herein are methods for treating, preventing, minimizing and/or substantially inhibiting inflammation associated with a respiratory virus such as COVID-19 and/or acute respiratory distress syndrome (ARDS), comprising administering to the lungs of a subject, by inhalation, a composition comprising an effective amount of an active agent such as a corticosteroid (for example, loteprednol etabonate (LE)). Also provided are pharmaceutical compositions comprising an active agent, such as a corticosteroid (for example, loteprednol etabonate (LE)) in an amount effective to treat, minimize and/or substantially inhibit inflammation associated with the respiratory virus, such as COVID-19 and/or ARDS.